Putnam Investments LLC boosted its position in Humana Inc (NYSE:HUM) by 10.7% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 58,931 shares of the insurance provider’s stock after purchasing an additional 5,693 shares during the period. Putnam Investments LLC’s holdings in Humana were worth $15,635,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of HUM. Whittier Trust Co. acquired a new position in Humana in the 2nd quarter worth about $27,000. Next Capital Management LLC acquired a new position in Humana in the 2nd quarter worth about $27,000. Advantage Investment Management LLC increased its holdings in Humana by 287.1% in the 2nd quarter. Advantage Investment Management LLC now owns 120 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 89 shares in the last quarter. Coastal Investment Advisors Inc. increased its holdings in Humana by 1,110.0% in the 2nd quarter. Coastal Investment Advisors Inc. now owns 121 shares of the insurance provider’s stock worth $33,000 after purchasing an additional 111 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Humana in the second quarter valued at about $36,000. 92.77% of the stock is owned by institutional investors and hedge funds.
Several brokerages have recently weighed in on HUM. Morgan Stanley increased their price target on Humana from $315.00 to $342.00 and gave the company an “overweight” rating in a research note on Friday, August 23rd. UBS Group increased their price target on Humana from $266.00 to $317.00 and gave the company a “neutral” rating in a research note on Thursday, August 1st. Deutsche Bank began coverage on Humana in a research note on Thursday, September 12th. They issued a “hold” rating and a $300.00 price target for the company. SunTrust Banks increased their price target on Humana to $340.00 and gave the company a “hold” rating in a research note on Thursday, August 1st. Finally, ValuEngine cut Humana from a “hold” rating to a “sell” rating in a research note on Wednesday, September 11th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have issued a buy rating to the company. Humana currently has a consensus rating of “Buy” and an average price target of $339.74.
Humana (NYSE:HUM) last released its earnings results on Wednesday, July 31st. The insurance provider reported $6.05 EPS for the quarter, topping the consensus estimate of $5.24 by $0.81. Humana had a return on equity of 22.47% and a net margin of 4.13%. The business had revenue of $16.25 billion during the quarter, compared to analysts’ expectations of $15.88 billion. During the same quarter last year, the firm posted $3.96 earnings per share. The firm’s revenue was up 13.9% on a year-over-year basis. On average, sell-side analysts anticipate that Humana Inc will post 17.67 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be paid a dividend of $0.55 per share. The ex-dividend date is Friday, September 27th. This represents a $2.20 annualized dividend and a yield of 0.79%. Humana’s dividend payout ratio is currently 15.12%.
In related news, insider Brian P. Leclaire sold 7,239 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the completion of the sale, the insider now owns 12,994 shares of the company’s stock, valued at $3,764,361.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.54% of the company’s stock.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Read More: What is the Bid-Ask Spread?
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.